Cardiovascular Diseases

Olema Oncology raises USD 54 Million for breast cancer program Olema Oncology has raised USD 54 million to push its lead program into the clinic and boost its R&D efforts in other areas.   The capital will bankroll a phase 1/2 study of the asset, OP-1250, as a single agent. Olema Oncology will assess the drug, a complete estrogen receptor antagonist, in patients with ER-positive, HER2-negative breast cancers that have come back despite other treatments or that have spread locally or to other parts of the body. The phase 1/2 dose-escalation trial is scheduled for the second half of 2020. The studies combining OP-1250 with other targeted breast ca...